Utilization Practices of Low Molecular Weight Heparin in Pediatric Patients with Acquired and Congenital Heart Disease

Author(s):  
Ashish A. Ankola ◽  
Muhammad B. Ghbeis ◽  
Brianna Bailey ◽  
Lori Sahakian ◽  
Amy Hellinger ◽  
...  
2021 ◽  
pp. 1-6
Author(s):  
Nadja Pardun ◽  
Julia Lemmer ◽  
Kristina Belker ◽  
Milka Pringsheim ◽  
Peter Ewert ◽  
...  

Abstract Background/hypothesis: Disadvantages of intravenous therapeutic unfractionated heparin, the first-line anti-coagulant agent in children with complex congenital heart disease, include unpredictable pharmacokinetics requiring frequent phlebotomies and the need for continuous intravenous access. Objective: To compare efficacy and safety of low-molecular-weight heparin administered by a subcutaneous indwelling catheter with intravenous unfractionated heparin. Materials and methods: Clinical data from 31 inpatients prospectively enrolled to receive subcutaneous low-molecular-weight heparin were compared with those from a historical group of 44 inpatients receiving intravenous unfractionated heparin. Investigation of parents’ satisfaction by telephone survey. Results: The percentage of anti-factor Xa levels outside therapeutic range was lower in the subcutaneous low-molecular-weight heparin group compared with the percentage of activated partial thromboplastin times outside therapeutic range in the intravenous unfractionated heparin group (40% versus 90%, p < 0.001). Neither group had a major complication. Transient local reactions occurred in 19% of patients of the subcutaneous low-molecular-weight heparin group. The number of needle punctures and that of placement of indwelling catheters were significantly lower in the subcutaneous low-molecular-weight heparin compared with the intravenous unfractionated heparin group (p < 0.001). In total, 84.2% of parents in the subcutaneous low-molecular-weight heparin group reported a positive experience when asked about comparison with prior intravenous unfractionated heparin treatment. Conclusion: Subcutaneous low-molecular-weight heparin offers a safe anti-coagulation regimen for children with complex congenital heart disease providing more efficient therapeutic anti-coagulation and a reduction in needle punctures, thus causing less pain and anxiety in this children.


Author(s):  
Kim-Lien Nguyen ◽  
Sarah Khan ◽  
John Moriarty ◽  
Kiyarash Mohajer ◽  
Pierangelo Renella ◽  
...  

Author(s):  
Natalie S. Shwaish ◽  
Lindsey Malloy-Walton ◽  
Keith Feldman ◽  
Kelli M. Teson ◽  
Jessica S. Watson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document